AbbVie unit wins $56 mln in US patent trial against Botox rival
I'm PortAI, I can summarize articles.
A Delaware federal jury ruled that Revance Therapeutics must pay AbbVie’s Allergan $56 million for patent infringement related to its anti-wrinkle drug Daxxify, which was found to mimic Allergan’s Botox manufacturing process. Allergan, which generated over $4.4 billion from Botox sales in the U.S. last year, sued Revance in 2021. Revance denied the allegations, claiming the patents were invalid. The case is Allergan Inc v. Revance Therapeutics Inc, U.S. District Court for the District of Delaware.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments